ArticleEuropean child & adolescent psychiatry2026
Global, regional and national burdens of schizophrenia in adolescents and young adults: a trend analysis and forecast from 1990 to 2021.
Article in European child & adolescent psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum β-catenin, GSK-3β, and IL-6 levels in medication-naive children with ADHD: a preliminary case-control study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Schizophrenia is a serious psychological illness that tends to occur during the teens or early adulthood years. It causes major disability and social impairment. However, few studies have examined its global burden among adolescents and young adults. This study utilised data from the 2021 Global Burden of Disease Study to evaluates long-term trends and forecasts the future burden in this age group. The global rate for age-standardized incidence rate (ASIR), Aprevalence rate (ASPR), and rate of disability-adjusted life years (ASDR) from 1990 to 2021 reduced gradually (AAPC < 0, p < 0.05). However, the actual number rose for incident from 0.41 million to 0.48 million, for prevalence from 1.71 million to 2.00 million, and for Disability-Adjusted Life Years(DALYs) from 1.14 million to 1.33 million. The rate for males was higher for both ASIR and ASDR for both sexes, and for both, the highest burden was in the group aged 20-24 years. Regionally, Australasia and East Asia showed the highest rates, while Eastern Europe reported the lowest. High-middle the Sociodemographic Index (SDI) countries carried the greatest burden. Inequality analyses indicated widening disparities, with greater concentration of burden in high-SDI regions. Decomposition analysis showed population growth as the main driver of increasing burden. Under the historical-trend continuation scenario, point estimates of ASIR, ASPR, and ASDR are projected to increase modestly through 2040, although prediction intervals widen substantially. Although age-standardized rates of schizophrenia among youth declined, the absolute burden increased due to demographic growth. The highest risks were observed in late adolescence and early adulthood, with males more affected than females. Regional and SDI disparities persist and may widen. Early detection and targeted interventions are needed to reduce the future burden of schizophrenia in young populations.
Indexed as
Identifiers
42714686What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.